Advanced Micro Devices
AMD
Market cap $158B

97.35 USD

+1.29

1.34%

At close Apr 30, 4:00 PM EDT

After hours

99.31

+1.96

2.01%

1 day

1.34%

5 days

6.29%

1 month

-5.25%

3 months

-18.10%

6 months

-34.49%

Year to date

-19.30%

1 year

-38.53%

5 years

85.82%

10 years

4,207.52%

About: Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.

Employees: 28,000

Technology Semiconductors

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 20 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5% less repeat investments, than reductions

Existing positions increased: 917 | Existing positions reduced: 961

8% less first-time investments, than exits

New positions opened: 318 | Existing positions closed: 345

1.18% less ownership

Funds ownership: 66.31% [Q3] → 65.13% (-1.18%) [Q4]

3% less funds holding

Funds holding: 2,495 [Q3] → 2,418 (-77) [Q4]

27% less capital invested

Capital invested by funds: $175B [Q3] → $128B (-$46.5B) [Q4]

33% less call options, than puts

Call options by funds: $14.6B | Put options by funds: $21.6B

48% less funds holding in top 10

Funds holding in top 10: 132 [Q3] → 69 (-63) [Q4]

See Fund Rankings

Research analyst outlook

20 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$95

2%

downside

Avg. target

$136

40%

upside

High target

$250

157%

upside

20 analyst ratings

14 positive

70%

6 neutral

30%

0 negative

0%

Seaport Global	13%upside $110	Buy Initiated	30 Apr 2025
Susquehanna Christopher Rolland 7% 1-year accuracy 9 / 124 met price target	39%upside $135	Positive Maintained	24 Apr 2025
Wedbush Matt Bryson 21% 1-year accuracy 8 / 38 met price target	18%upside $115	Outperform Maintained	23 Apr 2025
Bernstein Stacy Rasgon 40% 1-year accuracy 2 / 5 met price target	2%downside $95	Market Perform Maintained	22 Apr 2025
Barclays Tom O'Malley 36% 1-year accuracy 17 / 47 met price target	13%upside $110	Overweight Maintained	22 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 134 articles about AMD published over the past 30 days

WDC "Old Tech" Evolving with A.I., NVDA & AMD Still Important Holdings

Western Digital (WDC) is "in a good spot right now," according to Matthew Bryson. He cites its hard drive business and limited tariff exposure as signs that the "old tech" company has room to run with the next leg in A.I.

WDC "Old Tech" Evolving with A.I., NVDA & AMD Still Important Holdings

AMD's Real Upside Is Unpriced

AMD is expected to report Q1 2025 EPS of $0.94 on $7.11 billion revenue, +51.8% YoY. Forward P/E compressed to 22x despite 30%+ projected EPS CAGR through 2026, signaling deep market undervaluation. Data Center revenue surged 94% YoY in 2024, driving 28% segment margins and hyperscaler demand for MI300X and EPYC.

AMD's Real Upside Is Unpriced

These 2 Chip Stocks Could Be Better Bets Than Nvidia, Analyst Says

Seaport Research Partners began coverage of the leader in chips for artificial intelligence with a Sell rating.

These 2 Chip Stocks Could Be Better Bets Than Nvidia, Analyst Says

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology's Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

- Proprietary Multivalent Polymer (MVP) platform enables the engineering of potent, long-acting therapies - Proprietary Multivalent Polymer (MVP) platform enables the engineering of potent, long-acting therapies

Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology's Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

The Motley Fool

Better Semiconductor Stock: AMD vs. Nvidia

The PHLX Semiconductor Sector index has been under duress this year and lost over 14% of its value thanks to the tariff-fueled economic uncertainty that has raised the potential of a global recession, which explains why some of the major names in this sector have performed poorly on the stock market in 2025.

Better Semiconductor Stock: AMD vs. Nvidia

Zacks Investment Research

Advanced Micro Devices (AMD) Reports Next Week: Wall Street Expects Earnings Growth

Advanced Micro (AMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Advanced Micro Devices (AMD) Reports Next Week: Wall Street Expects Earnings Growth

24/7 Wall Street

Cathie Wood Braved the Trump Tariff Slump, Buying NVIDIA (Nasdaq: NVDA), AMD (Nasdaq: AMD) and Coinbase (Nasdaq: COIN)—Time to Follow Her?

Cathie Wood's Ark funds have been feeling extra pain at the hands of the recent Trump correction (or crash for portfolios that are heavily invested in high-multiple tech stocks), but that hasn't stopped her from buying the dip.

Cathie Wood Braved the Trump Tariff Slump, Buying NVIDIA (Nasdaq: NVDA), AMD (Nasdaq: AMD) and Coinbase (Nasdaq: COIN)—Time to Follow Her?

Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the company will present Phase 1/2a clinical and preclinical data on the company's adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD) at the 2025 ARVO Annual Meeting taking place May 4-8, 2025 in.

Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting

The Motley Fool

2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire

Artificial intelligence, or AI, is undeniably a massive opportunity with room for multiple big winners. Many of the most promising AI stocks have fallen out of favor recently thanks to economic uncertainty and AI spending concerns.

2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire

See News Rankings

Charts implemented using Lightweight Charts™